UC researchers open Phase 2 clinical trial to test new combination treatment for glioblastomas

A multidisciplinary team of University of Cincinnati Cancer Center researchers have opened a Phase 2 clinical trial to test a new combination treatment for glioblastomas (GBM), the most deadly form of brain tumors.

Otsuka terminates Alzheimer’s agitation drug after failed Phase 3

Otsuka ended development of AVP-786 after the experimental Alzheimer’s disease treatment failed a late-stage study earlier this year. The company made the decision to terminate

May 23, 2024

CymaBay maps out regulatory filing for primary biliary cholangitis drug seladelpar – Pharmaceutical Technology

CymaBay could file for approval of its compound seladelpar in PBC early next year. Image Credit: Shutterstock / SewCreamStudio CymaBay Therapeutics could file for a

September 21, 2023

FDA Clears AI-Powered Non-Invasive Skin Cancer Detector

The FDA cleared an artificial-intelligence (AI)-powered device designed to non-invasively detect skin cancer in the primary care setting, the agency announced on Tuesday. Developer DermaSensor

January 18, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.